Fig. 4From: PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical modelsRepresentative immunohistochemical analysis and relative Intensity Scores (0, +, ++) of PARP1, BRCA1, and RAD51 expression in patient-derived sarcoma specimensBack to article page